Stock comparison
ResMed
Veracyte
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.31B
Sector
Healthcare
VCYT
Veracyte
Market cap
$3.61B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | VCYT | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 50D | RMD |
| Benjamin Graham | 75B | 61D | RMD |
| Philip Fisher | 75B | 65C | RMD |
| Peter Lynch | 58C | 72B | VCYT |
| Joel Greenblatt | 47D | 50D | VCYT |
| Charlie Munger | 69B | 51D | RMD |
| Terry Smith | 73B | 56D | RMD |
Side-by-side metrics
| Metric | RMD | VCYT |
|---|---|---|
| Market cap | $30.31B | $3.61B |
| P/E (TTM) | 19.6x | 34.8x |
| EV/EBIT | 17.1x | 38.4x |
| ROIC (TTM) | 19.63% | 4.73% |
| Gross margin | 61.69% | 71.31% |
| Net margin | 27.44% | 16.25% |
| Revenue CAGR 5y | 12.64% | 23.89% |
| EPS CAGR 5y | 30.73% | - |
| Debt / Equity | 0.1x | 0.0x |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.31Bvs $3.61B+88%
- ROIC (TTM)19.63%vs 4.73%+76%
- EV/EBIT17.1xvs 38.4x+56%
VCYT leads on
- Debt / Equity0.0xvs 0.1x+77%
- Revenue CAGR 5y23.89%vs 12.64%+47%
- Gross margin71.31%vs 61.69%+13%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.